Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Pain Mechanisms in Patients With Bronchiectasis

29 de janeiro de 2019 atualizado por: Víctor Doménech, Universidad San Jorge

Characteristics of Underlying Pain Mechanisms in Patients With Bronchiectasis: a Cross-sectional Study

Pain mechanisms and their clinical impact in patients with bronchiectasis have not been investigated yet. The aim of the research is to assess the presence of central pain mechanisms in patients with bronchiectasis using the Quantitative Sensory Testing (QST) assumptions.

Visão geral do estudo

Status

Retirado

Condições

Intervenção / Tratamento

Descrição detalhada

Background and objective:

Recent findings suggest that pain can play an important role in terms of physical activity limitation in respiratory patients. Nevertheless, pain mechanisms and their clinical impact in patients with bronchiectasis have not been investigated yet. The objective of the observational study is to determine the somatosensorial profile in order to assess the presence of central pain mechanisms in patients with bronchiectasis.

Methodology:

Repeated-measures prospective cross-sectional study. A sample of patients diagnosed with bronchiectasis will be recruited and matched by age and sex with healthy controls. Pressure pain thresholds (PPTs), conditioned pain modulation (CPM) and referral pain will be assessed before and after the Incremental Shuttle Walking test (ISW). Levels of physical activity will be assessed using accelerometry during a 7-days period. Sleep quality (Pittsburgh sleep quality test), level of catastrophizing (Pain Catastrophizing Scale), level of sensitization (Central Sensitization Inventory) and level of anxiety and depression (Hospital Anxiety and Depression) will be assessed. The assessments will be done twice: 1) at baseline; and 2) at 6 months follow-up period.

Tipo de estudo

Observacional

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Espanha
    • Zaragoza
      • Villanueva de Gállego, Zaragoza, Espanha, 50830
        • Universidad San Jorge

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 90 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Adult patients diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase.

Descrição

Bronchiectasis Group

Inclusion Criteria:

  • Diagnosis of bronchiectasis by high-resolution computed tomography.
  • Ability to understand and perform all the clinical procedure.
  • Acquisition of informed consent.

Exclusion Criteria:

  • Diagnosis or clinical suspicion of cystic fibrosis by genetic test or sweat electrolytes test.
  • Diagnosis of rheumatic disease.
  • Being on a waiting list for lung transplantation.
  • Thoraco-abdominal surgery in the last 6 months.
  • Chronic use of pain medication.

Control Group

Inclusion Criteria:

  • Healthy subjects matched by age and sex with Bronchiectasis Group's subjects

Exclusion Criteria:

  • Be taking pain medication.
  • Presence of pain condition or pathology.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: Outro
  • Perspectivas de Tempo: Prospectivo

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Adult subjets
Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase, matched by by sex and age with healthy subjects.
Outro: Sem intervenção
Sem intervenção

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Referred pain area
Prazo: Baseline
Amount of pixels painted in an electronic body chart (Navigate Pain, Aalborg, Denmark) after supra threshold pain stimulus (STPS) in infraspinatus muscle.
Baseline

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of body areas affected by referred pain
Prazo: Baseline
Body chart is divided in 15 regions and the frequency of pain in each one is registered after STPS
Baseline
Pain intensity after supra threshold pain stimulus (STPS)
Prazo: Baseline
Level of pain in a visual analogue scale from 0 to 10 after STPS
Baseline
Pressure pain thresholds (PPTs)
Prazo: Baseline
Level of pressure tolerated by the patient just before feel pain. The pressure is done with an algometer (SB-MEDIC Electronics, Solna, Sweden). PPTS will be assessed bilaterally in infraspinatus, supraspinatus and medial gastrocnemius muscles.
Baseline
PPTs with a Conditioned Pain Modulation (CPM) pressure stimulus
Prazo: Baseline
Level of pressure tolerated by patient just before feel pain. The conditionated pressure stimulus is preform by a blood pressure cuff. CPM will be assessed bilaterally in infraspinatus, supraspinatus and medial gastrocnemius muscles.
Baseline
Total physical activity time
Prazo: 7 days period
Total time spent per day in physical activities at different intensities equal or superior to 100 counts per minute (≥100 cpm), obtained by accelerometry (Actigraph gt3x+).
7 days period
Sedentary behaviour time
Prazo: 7 days period
Total time spent per day in physical activities at different intensities inferior to 100 cpm (<100 cpm).
7 days period
Light physical activity time
Prazo: 7 days period
Total time spent per day in physical activities at intensities between 100 and 1951 cpm (100-1951 cpm).
7 days period
Moderate-Vigorous physical activity time
Prazo: 7 days period
Total time spent per day in physical activities at intensities equal or superior to 1952 cpm (≥1952 cpm).
7 days period
Level of catastrophizing
Prazo: Baseline
Punctuation obtained in Pain Catastrophizing Scale (PCS). It comprises 13 items which focus on thoughts and feelings encountered while experiencing pain. Each item is scored from 0 (not at all) to 4 (all the time) with a total PCS score range from 0-52 points, where higher scores indicating higher levels of pain catastrophizing.
Baseline
Level of sensitization
Prazo: Baseline
Punctuation obtained in Central Sensitization Inventory (CSI). CSI assesses 25 health-related symptoms common to Central Sensitivity Syndromes. Responses are recorded about the frequency of each symptom, with a Likert scale from 0 (never) to 4 (always), resulting in a total possible score of 100. Higher scores are associated with a higher degree of self-reported symptomology.
Baseline
Level of anxiety and depression
Prazo: Baseline
Punctuation obtained in Hospital Anxiety and Depression (HAD). The HAD is a 14-item self-report scale measuring the presence of symptoms of both anxiety (seven items) and depression (seven items) during the past week. Each item is scored from 0 to 3, so the final score for each subscale is between 0 and 21. The majority of the studies use the cutoffs of 7/8 for possible and 10/11 for probable anxiety or depression.
Baseline
Quality of sleep
Prazo: Baseline
Punctuation obtained in Pittsburgh Sleep Quality Index (PSQI). The PSQI is a 19-item, self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. Each sleep component yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. Sleep component scores were summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.
Baseline
Level of resilience
Prazo: Baseline
Punctuation obtained in Brief Resilience Scale (BRS). This is a 6-item self-report scale with a 5-point response scale ranging from 1 (strongly disagree) to 5 (strongly agree). A higher score indicates a higher degree of resilience.
Baseline
Distance in ISW test
Prazo: Baseline
Meters reached in the ISW test.
Baseline
Changes in referred pain area
Prazo: Baseline and after 6 months follow-up
Amount of pixels painted in an electronic body chart (Navigate Pain, Aalborg, Denmark) after supra threshold pain stimulus (STPS) in infraspinatus muscle.
Baseline and after 6 months follow-up
Changes in number of body areas affected by referred pain
Prazo: Baseline and after 6 months follow-up
Body chart is divided in 15 regions and the frequency of pain in each one is registered after STPS
Baseline and after 6 months follow-up
Changes in pain intensity after supra threshold pain stimulus (STPS)
Prazo: Baseline and after 6 months follow-up
Level of pain in a visual analogue scale from 0 to 10 after STPS.
Baseline and after 6 months follow-up
Changes in pressure pain thresholds (PPTs)
Prazo: Baseline and after 6 months follow-up
Level of pressure tolerated by the patient just before feel pain. The pressure is done with an algometer (SB-MEDIC Electronics, Solna, Sweden)
Baseline and after 6 months follow-up
Changes in Pressure Pain Thresholds (PPTs) with a Conditioned Pain Modulation (CPM) pressure stimulus
Prazo: Baseline and after 6 months follow-up
Level of pressure tolerated by patient just before feel pain. The conditionated pressure stimulus is preform by a blood pressure cuff
Baseline and after 6 months follow-up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Universidad San Jorge

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

29 de setembro de 2017

Conclusão Primária (Antecipado)

31 de outubro de 2019

Conclusão do estudo (Antecipado)

30 de novembro de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

19 de outubro de 2017

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de dezembro de 2017

Primeira postagem (Real)

18 de dezembro de 2017

Atualizações de registro de estudo

Última Atualização Postada (Real)

31 de janeiro de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de janeiro de 2019

Última verificação

1 de janeiro de 2019

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • PI17/0290

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Sem intervenção

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Russia

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever